Feed TNXP
TN

Tonix Pharmaceuticals Holding Corp. TNXP · NASDAQ

$5.13 -5.52% (-$0.30)

Market cap
$88.0M
Enterprise value
-$87.0M
P/E
-
Forward P/E
-
PEG
-
P/S
3.0x
P/FCF
-
EV/EBITDA
-
ROIC
-74.0%
Gross margin
80.2%
Net margin
-548.6%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
1.79
Free float
99.6%

About the company

Tonix Pharmaceuticals Holding Corp. (TNXP) is a biopharmaceutical company focused on developing drugs for the treatment of psychiatric and neurological disorders. Their main product candidates include medicines for the treatment of post-traumatic stress disorder (PTSD), fibromyalgia, and migraines. Tonix Pharmaceuticals focuses on utilizing advanced biotechnological methods and clinical trials to discover new treatment options for patients suffering from these conditions. The company is active in research and development and conducts clinical trials to assess the efficacy and safety of its medicinal products. Tonix Pharmaceuticals Holding Corp. (TNXP) shares could be suitable for investors looking for opportunities in the biopharmaceutical sector with a focus on the treatment of psychiatric and neurological disorders.

Sector

Healthcare

Industry

Biotechnology

CEO

Seth Lederman

Employees

142

Headquarters

Berkeley Heights

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy